US FDA approves GSK's twice-yearly asthma drug
16/12/2025 23:08
Corrects paragraph 1 to say the drug was approved to treat 'severe' asthma, and remove reference to approval for a chronic inflammatory sinus condition LONDON, Dec 16 (Reuters) - The U.S. health regulator has approved GSK's GSK.L add-on drug to treat severe asthma, the drugmaker said on Tuesday, paving the way for a less frequently dosed treatment option for patients to enter the market. (Reporting by Bhanvi Satija in London, Sahil Pandey and Sneha S K in Bengaluru; Editing by Tasim Zahid and Shailesh Kuber) ((Bhanvi.Satija@thomsonreuters.com;))
Recent news on Regeneron Pharmaceuticals
See all newsLilly, Regeneron selected for US program to review new manufacturing plants faster (updated)
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
Brief: Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities - CNBC
Brief: Cemdisiran Regulatory Submissions Accepted For Review By FDA And EMA For The Treatment Of Generalized Myasthenia Gravis (Gmg)
AbbVie sharpens immunology focus with $10.9 billion Apogee deal (updated)